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Abstract
The goal of the NIH funded A.S.P.E.N. 2017 research workshop (RW) “Gastric Bypass: Role of 
the Gut”, was to focus on the exciting research evaluating gut-derived signals in modulating 
outcomes post bariatric surgery. Though gastric bypass surgery has undoubted positive effects, the 
mechanistic basis of improved outcomes cannot be solely explained by caloric restriction.
Emerging data suggest that bile acid metabolic pathways, luminal contents, energy balance, gut 
mucosal integrity as well as the gut microbiota are significantly modulated post bariatric surgery 
and may be responsible for the variable outcomes, each of which were rigorously evaluated.
The RW served as a timely and novel academic meeting that brought together clinicians and 
researchers across the scientific spectrum, fostering a unique venue for inter-disciplinary 
collaboration among investigators.
It promoted engaging discussion and evolution of new research hypothesis and ideas, driving the 
development of novel ameliorative, therapeutic and non-surgical interventions targeting obesity 
and its co-morbidities.
Importantly, a critical evaluation of the current knowledge regarding gut modulated signaling post 
bariatric surgery, potential pitfalls and lacunae were thoroughly addressed.
CORRESPONDING AUTHOR: Ajay K. Jain, Department of Pediatrics, Saint Louis University, SSM Cardinal Glennon Hospital, 
1465 South Grand Blvd., St. Louis, MO 63104, USA. ajay.jain@health.slu.edu. 
HHS Public Access
Author manuscript
JPEN J Parenter Enteral Nutr. Author manuscript; available in PMC 2019 February 01.
Published in final edited form as:














Obesity is a global health problem and its ameliorative strategies remain a major research 
focus1,2. Though several interventions have been trialed, the mainstay of current therapy 
anchors on lifestyle modification inclusive of nutrition and exercise3–5. While clinically 
meaningful weight loss may be achieved with lifestyle intervention, such weight loss is 
generally not sustained and its efficacy in modulating comorbidities has been questioned6. 
Thus, there remains an ongoing need for effective and durable therapeutic options, including 
bariatric surgery.
With surgical advances patients with obesity tend to have significant improvement in obesity 
related co-morbidities with gastric bypass surgery. While several variations for such bariatric 
surgery are in practice, one of the earliest was the Roux-en-Y gastric bypass (RYGB)7. Post-
surgery improvement in most organ systems affected by obesity have been noted8.
In keeping with significant health benefits, the number of patients undergoing bariatric 
surgery has reached unprecedented levels, with over 300,000 bariatric surgery procedures 
being undertaken annually9,10. Given the remarkable success, the underlying mechanisms 
leading to improved outcomes after bariatric surgery are the focus of a burgeoning field of 
research that may lead to novel non-surgical interventions.
Recent data suggests that post-surgery improvement may not merely be an effect of weight 
loss; there may be a significant influence of altered gut derived signals in modulating the 
disease pathology. Alterations in gut anatomy also induce adaptive changes to the 
morphology of the gut, which affect the absorption of macro and micronutrients. The 
mechanisms responsible for metabolic and nutritional outcomes following gastric bypass 
were reviewed as part of the workshop and presented by each faculty member.
(I) Overview of Enterohepatic Circulation, Gut Microbiota and Metabolic Pathways Relevant 
to the Gut-liver Axis: (Ajay K Jain)
Gastric Bypass FXR and Bile Acids—Emerging studies suggest that bile acid 
metabolic pathways are disrupted with bariatric surgery with significant alterations to the 
finely regulated enterohepatic bile acid circulation11,12. Bile acids, traditionally considered 
as toxic agents have emerged as major signaling molecules maintaining several homeostatic 
pathways involved in insulin, glucose metabolism, lipid regulation as well as regulators of 
hepatic steatosis13,14. Marked increases in serum bile acids and its sub-fractions have been 
noted post RYGB in comparison to weight matched controls12,15. New research provides 
evidence that enteral bile acid treatment activates the nuclear receptor, Farnesoid X Receptor 
(FXR) in gut epithelial cells16,17. Such activation stimulates the production of the growth 
factor, Fibroblast Growth Factor – 19 (FGF19). FGF19 is subsequently delivered via the 
portal system to the liver and is known to modulate bile acid, glucose and lipid 
metabolism18,19. In fact, intravenously delivered FGF19 has been shown to reverse or 
prevent diabetes, improve glycemic control and reduced hepatic steatosis and triglyceride 
levels20–22. FGF19 thus functions as a secretory signal from the gut to the liver, regulating 
bile acid synthesis23.
Jain et al. Page 2













This seems to provide evidence that hepatic bile acid synthesis; glucose and lipid 
metabolism is modulated via gut FXR signaling24–26. Indeed, higher levels of FXR and 
FGF19 have been noted several months post RYGB in human subjects27.
Both large animal studies and human studies have shown that exogenously delivered FXR 
agonist improve glycemic control, lipid metabolism and hepatic steatosis28,29. Additionally 
surgical procedures involving ileal transposition (where sections of the ileum are inserted 
into the jejunum), result in a significant increase in bile acids levels, improvement in body 
mass and obesity related co-morbidities30.
A postulated mechanism has been a short circuiting of the normal enterohepatic circulation 
brought about by the altered anatomy, as the ileum is the primary site of bile acid absorption. 
Improved glycemic regulation, reduced hepatic steatosis, increased bile acid levels, as well 
as weight loss have been noted in animal models with biliary diversion31,32. The 
recapitulation of the benefits of gastric bypass using such procedure raises the thought 
provoking idea that anatomic alteration during bariatric surgery may explain some of the 
mechanistic basis of improved outcomes. However, while this data is encouraging it has also 
been noted that there are differences in post prandial bile acids after RYGB or Vertical 
sleeve gastrectomy (VSG) which points to a differential enterohepatic signaling based on the 
type of surgery33,34.
Further exploration of such bile acid regulated key signaling pathways with a potential for 
pharmacological and nutritional intervention was a major focus of the 2017 RW.
Gastric Bypass and role of Glucagon Like Peptide-1 (GLP-1) and TGR5 axis—
A further mechanistic link is again through bile acid regulated pathways. Bile acids activate 
TGR5 – a cell surface G-protein-coupled receptor35. TGR5 is known to be present in the 
intestines, brown adipose tissue and the liver36. There is an increase in intracellular cAMP 
upon bile acid stimulation of TGR5 with variable effects dependent on the cell type 
expressing TGR537. The role of bile acids in regulation of glucose homeostasis is further 
strengthened by the secretion of GLP-1 upon TGR5 activation38,39.
We now know that plasma GLP-1 rapidly increases after RYGB40. GLP-1 has been 
implicated in glycemic homeostasis. Along with glucose dependent insulinotropic 
polypeptide (GIP), GLP-1 is a major gut hormone which enhances the insulin response to 
nutrient ingestion41. In non-obese individuals with normal glucose tolerance GLP-1 is 
released in response to nutrient intake. However, this GLP-1 response is significantly 
diminished in those with obesity42. It is known that post RYGB there in an increased TGR5 
signaling12. Given that GLP-1 is secreted from enteroendocrine L cells in the intestine, it is 
plausible that manipulation of the gastro-intestinal tract as in RYGB alters GLP-1 secretion.
Further highlighting this pathway is data that postoperatively there is enhancement of 
postprandial GLP-1 response43,44. GLP-1 response is known to be greater after RYGB than 
after Sleeve Gastrectomy45. Additionally, such increase in GLP-1 response was not noted in 
calorie restricted obese patients; mimicking the post-surgery diet46 or in obese patients on a 
low-calorie diet experiencing a similar weight loss. It has also been shown that there is a 
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progressive increase in GLP-1 level during the first year postoperatively with a sustained 
response noted in some individuals47–49.
Given the above data it appears plausible that alterations to GLP-1 and the TGR5-GLP axis, 
brought about by the surgical procedure of Gastric bypass exert significant beneficial 
influence and the therapeutic potential needs to be explored.
Gut Microbiota FXR and TGR5—While the bacterial mass in any individual is a small 
percent of body weight50, the bacterial genome exceeds by several folds the human genome. 
Ironically this makes us genetically 1% human and 99% bacterial51,52.
When viewed as a whole, this “super gut microbial organism” can perform vital physiologic 
functions53. These typically benefit the host in educating the mucosal immune system, 
nutrient extraction from undigested carbohydrates, production of short chain fatty acids, 
production of vitamins and metabolism of bile acids54,55.
A large human study evaluating fecal microbial colonies in dizygotic and monozygotic twin 
pairs addressed the role of host genetic factors, adiposity, environment and its influence on 
the gut microbiota56. Although the human gut microbiota was shared among family 
members, it was specific for each individual. A comparable co-variation between dizygotic 
and monozygotic twin pairs excluded difference based on genetic factors. Obesity was 
associated with intestinal microbiomes showing reduced diversity at a phylum level56.
In rodent studies, delivery of cecal microbiota from ob/ob mice into wild germ free animals 
resulted in a modest fat gain. Such bacterial transfer also increased food calorie extraction in 
comparison to animals receiving gut bacteria from lean animal donors57. Several studies 
evaluating Nonalcoholic steatohepatitis (NASH), have noted improvement in steatosis, 
glucose intolerance as well as lipid profiles58,59 with exogenous gut bacterial 
modulation60,61.
These studies further support the belief that gut bacteria modulate and play an important role 
in human disease. Several rodent and human studies have shown that post RYGB there 
occurs a restructuring of the gut microbiota62,63. An exogenous transfer of the gut microbes 
from RYGB mice to un-operated, germ-free mice resulted in significant reduction in fat 
mass gain as well as less weight gain in comparison to such a transfer from mice that 
underwent sham surgery64.
Given that gut microbes are intimately involved in gut nutrient processing and their 
alterations are noted with RYGB, it is reason to believe that altered gut microbiota secondary 
to gastric bypass influences positive outcomes post RYGB surgery.
(II) Gut Hormones and Bariatric Surgery: (Carel Le Roux)
Gut hormones have been implicated as part of the mechanisms of how bariatric surgery 
reduces bodyweight and maintains long term weight loss65.
RYGB and VSG might alter signaling from the gut to the hypothalamus and brainstem. 
Markedly higher postprandial levels of the anorexigenic hormone peptide YY (PYY)66 are 
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noted after both RYGB and VSG, but not after calorie restriction or adjustable gastric 
banding (AGB)67,68. After a meal, PYY is released from the L cells in the distal small bowel 
in proportion to consumed calories. It decreases food intake by acting at the arcuate nucleus 
of the hypothalamus69, and also via vagal afferents ending at the nucleus of the solitary 
track, thus signaling satiety. PYY has been shown to delay gastric emptying and increase 
energy expenditure70. Patients with increased PYY after RYGB have more weight loss71,72. 
Blocking the release of PYY with octreotide increased food intake in humans and rats after 
RYGB, but not AGB. Mechanistic studies have also shown the physiological importance of 
PYY in rodent studies. GLP-1 responses are similar to those of PYY after both RYGB and 
VSG73. GLP‑1 is secreted by the L cells of the small bowel together with PYY, with higher 
concentrations in the colon and distal ileum. It acts on the GLP‑1 receptors in the 
hypothalamus, striatum, substantia nigra and brainstem74. In response to a meal the peptide 
is produced, which decreases food intake via its effects on the brainstem and 
hypothalamus75. GLP‑1 delays gastric emptying, inhibits the release of glucagon and acts 
on the pancreas to promote secretion of insulin76. Whether GLP‑1 alone is necessary for 
VSG-induced weight loss has been questioned. The procedure was effective equally in 
GLP‑1 receptor wild-type and knockout mice77 but the potential synergy of GLP-1 along 
with other gut hormones post these operations may hold the key. The rapid nutrient delivery 
to the distal ileum after RYGB might be responsible for the exaggerated increase of both 
GLP-1 and PYY levels78. In the absence of a shorter small bowel in VSG, the rise in levels 
of these gut hormones has been attributed to rapid gastric emptying79. However, this finding 
is probably just part of the story as nutrient sensing in the proximal segment of the small 
bowel can produce signal to the distal small bowel to release gut hormones80. Recent data 
also suggests that post RYGB there is an increase in the post prandial responses for 
cholecystokinin and glucagon and a decrease in ghrelin and leptin81. It is also known that 
gut hormones are elevated within days after surgery and remain elevated for at least a decade 
after RYGB47. However, although they play an important role the gut hormones are only 
part of the mechanistic explanations for why bariatric surgery is able to reduce weight and 
maintain weight loss.
(III) Role of Bile Salts and Key Hepatobiliary Receptors in Modulating Gut Structure and 
Signaling Post Gastric Bypass Surgery (Puneet Puri)
Weight loss in the management of obesity is plagued by the lack of effective long term 
sustainability and translation into improved outcomes6,82. The most notable obesity related 
liver condition is nonalcoholic fatty liver disease (NAFLD). More concerning is the fact that 
NASH, the aggressive phenotype of NAFLD, is emerging as the leading cause of cirrhosis, 
liver cancer and liver transplantation83,84.
Bariatric surgery remains a very important approach to combat obesity and its co-
morbidities85. The benefits of bariatric surgery extend beyond weight loss and are postulated 
to occur via modulation of glucose and lipid homeostasis, which in turn are also regulated 
by bile acids86. Given alterations noted in serum bile acid levels following gastric bypass 
surgery in both human and animal studies12,87, several authors have postulated that the 
beneficial effects post-surgery are a result, at least in part, due to changes in enterohepatic 
circulation of bile acids88.
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Experimental approaches such as ‘ileal transposition’ or bile diversion have been used in 
preclinical studies. Ileal transposition studies in rodent models demonstrate diminished food 
intake, significant weight loss and resolution of the features of the metabolic syndrome89. 
These improvements are linked to adaptation of the interposed segment as evident by greater 
length of jejunum-like villi, enhanced mucosal surface area, as well as increase in mRNA 
expression of transcription factor GATA4/ileal lipid binding protein (GATA4/ILBP)30. 
Additionally, ileal transposition short-circuits enterohepatic recycling of the bile acids that 
lead to protective effects against the metabolic syndrome30. Importantly, weight loss alone 
does not improve the metabolic effects as is seen in rodents with similar weight loss on food 
restriction, but are observed in surgical weight loss procedures that alter serum bile acids and 
have been noted to help in the resolution of NASH90.
While data translated from these studies is certainly helpful in defining mechanistic links, it 
is plausible that additional bile acid pathways are modulated by current bariatric surgery 
procedures as there is a known variability in the serum bile acid levels based on the kind of 
surgery performed34,91.
In fact, VSG with gastroduodenal continuity is becoming the preferred surgical option for 
obesity in recent years92. In addition to weight loss, VSG can produce changes in bile acids 
and their receptor mediated molecular actions confer the metabolic benefits93. We now know 
that FXR is “a” target for the beneficial weight-loss dependent and independent effects of 
VSG, similarly its downstream targets small heterodimer partner (SHP) and indirect entero-
hepatic signal FGF15/19 also merit future investigation as potential therapeutic targets94. 
Further mechanistic insights into bile acid signaling and regulation of entero-hepatic 
circulation will advance our understanding of bariatric surgery related metabolic benefits. In 
future, this will allow translation of these metabolic benefits through non- or minimally 
invasive “bariatric-mimetic” interventions that would bridge the current vast therapeutic gap 
in patients suffering from obesity and other related comorbidities including NASH95.
(IV) Changes in intestinal metabolism and portal signaling (Ali Tavakkoli)
Mechanisms leading to the anti-diabetic effects of bariatric surgery remain poorly 
elucidated. Understanding these mechanisms can lead to development of less invasive 
surgical or medical alternatives that can be offered to a wider patient population. There has 
been a broad interest in the changes in intestinal function that occurs after RYGB surgery, 
with studies showing increase in intestinal glucose utilization after surgery96. Furthermore, 
studies have also shown a decrease in intestinal glucose absorption after RYGB97,98. It has 
been postulated that these changes in intestinal function, alter fasting and post-prandial 
portal vein milieu which can alter hepatic glucose handling and lead to the early reduction in 
hepatic insulin resistance that is seen after bariatric surgery. To support this hypothesis, 
studies using portal vein infusions in a rodent model, have shown post-infusion changes in 
expression of hepatic enzymes involved in glucose homeostasis, through a neutrally 
mediated process that likely involves SGLT3 as a portal glucose sensor97. The authors 
concluded that the portal vein was not only capable of sensing its glucose levels but 
responded to it by altering hepatic glucose handling.
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The portal vein delivers the intestinal venous drainage to the liver and as such provides a 
direct communication between the bowel and the liver. The above mentioned studies which 
show that the portal vein is more than a simple conduit between the bowel and the liver, and 
the observation that changes in portal vein glucose levels can lead to changes in hepatic 
pathways involved in glucose homeostasis97,99, through a neutrally mediated pathway, 
highlight an important role for this structure in post-operative glucose improvement.
To this effect studies have documented a decrease in fasting and post-prandial glucose levels 
after RYGB surgery in rodents, with associated decrease in hepatic gluconeogenesis and 
glycolysis. Interestingly, some of these changes are uniquely seen in RYGB and not VSG, 
which may explain the more potent anti-diabetic effects of RYGB. Further research may 
provide insights into the mechanistic basic of these responses.
(V) Gut Nutrient Sensing: Gut Remodeling and Adaptation to Gastric Bypass and Effects 
on Absorption of Macro and Micronutrients (Nana Gletsu-Miller)
Gastric bypass surgery is traditionally considered to be malabsorptive100, however, from the 
stand point of nutrition this characterization is simplistic. Several mechanisms contribute to 
the risk of malnutrition observed following RYGB. One major issue is the reduced dietary 
intake of macro and micronutrients, secondary to decreased energy intake and to food 
intolerances that develop after surgery101,102. In addition patients decrease their intake of 
dietary factors that enhance absorption including fat and vitamin C, which leads to decreased 
bioavailability of nutrients such as vitamin D, iron and copper. Besides changes in dietary 
intake, anatomical changes result in reduced nutrient bioavailability and intestinal 
absorption. Resection of the stomach antrum decreases gastric acid secretion103,104 and loss 
of absorptive surface in the duodenum and proximal jejunum reduces access to nutrient 
transporters105. At the same time, the adaptive response to changes in the anatomy result in 
growth of the remaining small intestine, similar to the adaptation of the gut that occurs after 
resection of the intestine, referred to as short gut syndrome106. The result of these changes is 
an increase the absorption of some nutrients but not others after RYGB107. Therefore the 
impact of RYGB on nutritional status is mixed with respect to macro and micronutrients.
Impact on macronutrient status—As aforementioned changes in gut anatomy, 
accompanied by intestinal hyperplasia106,108 lead to changes in macronutrient absorption. 
Over the long term, the gut retains or enhances its ability to absorb glucose109, fatty acids110 
and amino acids111,112. Elegant studies in rodents and humans demonstrated that gut 
adaptations can lead to improvements in glucose metabolism, as the intestine assists with 
glucose disposal from the periphery109. At one and six months post gastric bypass, it has 
been demonstrated that even though patients decreased their dietary intake of fat, they did 
not exhibit deficiencies in essential fatty acids113. However, enhanced absorption of amino 
acids does not compensate for the fact that many patients do not meet the dietary intake of 
60 g of protein that is recommended for this population114,115. The evidence supporting this 
recommendation was rated as low; information on the impact of dietary protein on protein 
status during surgically-induced weight loss is mostly observational116 and evidence from 
randomized clinical trials is extremely limited117. This is an important issue since 
sarcopenia is common after surgery, with patient losing 10 to 28% of lean mass116. The 
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clinical manifestations of a reduction of lean body mass and sarcopenic obesity include 
decreased energy expenditure118, muscle strength119, and bone density118, adverse outcomes 
that have the potential to reduce the benefits of surgery over the long term.
Impact on micronutrient status—Unlike macronutrients, patients undergoing RYGB 
are more vulnerable to deficiencies in micronutrients, primarily minerals and fat soluble 
vitamins. It has long been appreciated that nutritional complications such as hair loss, bone 
loss, anemia, fatigue, neuropathies120, and more severe symptoms including bone 
fractures121, blindness122 and paralysis123, associated with deficiencies in micronutrients 
can occur following gastric bypass. Unfortunately, the literature regarding the micronutrient 
status of RYGB is incomplete due to the lack of patient follow-up and nutritional screening. 
Our best knowledge is that deficiencies in iron, calcium and vitamin D are common, ranging 
from 25 to 75%120. Deficiencies in vitamins A, B12 and other B vitamins occur less 
frequently with incidences of around 10%124,125 The mechanisms responsible are complex 
since obesity per se, prior to surgery, is a risk factor for deficiency in specific nutrients, such 
as vitamin D126 and iron127. In the obese state, the bioavailability of iron and vitamin D is 
reduced due to obesity-induced inflammation128 and sequestration in adipose tissue129, 
respectively. Following surgery, as patients experience weight loss, this alleviates the 
adverse impact on the nutritional status that is related to obesity130,131. Despite the favorable 
impact of weight loss, research shows that the nutritional status of vitamin B12, iron, zinc, 
copper, and calcium worsens after surgery120. This may be due to resection of the stomach 
and the resulting decrease in gastric acid secretion59,60. Gastric acid is needed to digest the 
minerals from food, and solubilize them, so that they are bioavailable for absorption. 
Moreover, to reduce the risk of stomach ulcers after surgery, patients increase their use of 
proton pump inhibitors132, and hypogastric acidity impairs the absorption of nutrients133. 
Bypass of the proximal intestine, which is where the majority of the transporters of minerals 
are located, also contributes to the reduced absorption of iron105, zinc105, and vitamin D134 
that has been observed after surgery. It is not clear whether gut adaptation, over the long 
term, can rescue the defects in intestinal absorption of micronutrients135–138.
Strategies for prevention and treatment—The risk of malnutrition following RYGB 
reduces its safety profile. Adverse outcomes related to function and quality of life139,140 
would be reduced if nutritional support of these patients was improved. Therefore patients, 
practitioners, and other stakeholders need to know the best practices for the treatment and 
prevention of nutritional deficiencies114. Studies have demonstrated that sufficient intake of 
protein and iron, can realistically be obtained from diet especially if it is nutrient 
dense115,141. Use of dietary supplements is also an effective way to manage status of 
protein142, calcium, iron141,143, and vitamins D115 and B12144 after gastric bypass. For 
treatment of deficiencies, although clinical trial are limited, data suggest that high-dose 
supplementation of iron145, vitamins D142,146 and B12 and protein117 is effective. Taken 
together, since oral ingestion of food and supplements can be used to prevent and treat 
malnutrition, this suggests that sufficient capacity of the gut remains for digestion and 
absorption of micronutrients after surgery. However, it has also been advocated for patients 
to undergo intravenous administration of nutrients, as a second line of therapy114,147. In 
summary, more research is needed to determine optimum strategies for treatment and 
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prevention of nutritional deficiencies post gastric bypass surgery. This information will 
improve nutritional outcomes so that more patients can benefit from this life-saving 
procedure.
(VI) Effect of Microbiota on Digestion and Absorption: Integrity of the Mucosal Barrier 
(Bruce M. Wolfe)
The extent to which obesity contributes to the development and severity of obesity-related 
comorbid conditions such as type 2 diabetes, hypertension, dyslipidemia, and obstructive 
sleep apnea generally increases with the severity of obesity but is highly variable148. There 
are both genetic and environmental factors which contribute to obesity-related comorbid 
disease, including certain alterations of the composition of the microbiome. Efforts to 
determine causality are the subject of ongoing research.
In addition, weight loss is highly variable among people with obesity following interventions 
including lifestyle intervention, pharmacotherapy, and bariatric surgery/gastric bypass149. 
Efforts to explain or predict the extent of this variable weight loss following gastric bypass 
remain largely unknown. While, the NIH multi-center consortium, Longitudinal Assessment 
of Bariatric Surgery, identified changes in eating behaviors that contribute modestly to this 
variation150, further research is necessary into the potential contributions by genomic factors 
as well as changes of the microbiome induced by gastric bypass to identify appropriate 
candidates. Though mechanisms indicating a direct relationship between gut microbiota 
changes and response to gastric bypass remain a major focus of research, we know that the 
gut microbiota in mammals plays an important role in the digestion, absorption, and 
extraction of energy from ingested nutrients151. The importance of this energy extraction 
varies among mammalian species. For example, in cows, as much as 70% of total energy 
extraction from the diet results from fermentation production of short-chain fatty acids. 
Germ-free mice require approximately 30% greater energy intake in order to achieve 
comparable growth to normally colonized mice. The contribution from microbiota digestion 
of nutrients in humans is estimated to represent approximately 10% of total energy, a figure 
that potentially varies widely.
The mammalian proximal intestine absorbs simple carbohydrates efficiently, especially 
glucose. Disaccharides are also absorbed and, to a limited extent, polysaccharides. 
Otherwise indigestible carbohydrates in the proximal intestine pass distally for digestion and 
metabolism by luminal microbiota. Fermentation in which polysaccharides are metabolized 
to short-chain fatty acids is an important pathway. Pyruvate is metabolized to acetyl-CoA 
and ultimately acetate, butyrate and propionate152. Butyrate and acetate are readily absorbed 
and contribute to energy supply, particularly for enterocytes. Butyrate has been identified as 
a modifier of cytokine production by CT cells and to enhance the integrity of the intestinal 
epithelial barrier. Metabolic signaling is also attributed to absorbed butyrate153. Acetate has 
a role in enhancing the resolution of intestinal inflammation and protection from intestinal 
pathogens.
In summary, gut microbiota is responsible for the digestion of otherwise indigestible 
carbohydrates and, to a lesser extent, protein and lipids. The contribution of these processes 
to total energy supply will vary as functions of dietary intake, microbiome composition, and 
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other factors involved in digestion of nutrients including bile salts, and pancreatic and other 
enzymes154. One measure of qualitative detection of the microbiota effect on digestion is the 
production of both methane and hydrogen. These gases are excreted in the breath and may 
be detected qualitatively if not quantitatively, reflecting bacterial digestion. Since gut 
anatomy is altered post bariatric surgery there is data confirming an associated change in the 
microbiota. Whether such change this is a cause or has a major effect post bariatric surgery 
needs further investigation.
Low levels of chronic inflammation are variably associated with obesity. This low level 
inflammation is associated with atherosclerosis, insulin resistance, type 2 diabetes as well as 
non-alcoholic steatohepatitis152. The activation of inflammatory cells in fat stores involves 
the action of cytokines, chemokines, and acute phase reactants. Triggers of inflammatory 
cells include adipocyte apoptosis, saturated free fatty acids, ceramides, glucose, and low 
levels of endotoxemia (LPS).
LPS-binding protein (LPB) serves as a surrogate marker of underlying low-grade 
endotoxemia induced by LPS from the gut. The absorption of LPS is attributed to increased 
permeability of the intestinal barrier induced by alterations of the microbiome among other 
factors. Levels of LPB, BMI, and obstructive sleep apnea have all been shown to be 
associated in children155. New data also shows that short term decrease in LPS is 
additionally dependent on the type of the surgical procedure as well as on the glycemic 
status of a patient156. In mice, a high fat diet induced changes of the microbiome are 
associated with endotoxemia, suggesting a relationship between diet-induced changes of the 
microbiome, intestinal permeability to endotoxins, and related systemic inflammation157. 
This may provide a link between the association of the gut microbiome and cardio/metabolic 
health158. As changes in the flow of the food stream post bariatric surgery can alter the 
microbiota, it seem intuitive to believe that these microscopic organisms may prove 
formidable players in outcomes post such surgery.
Microbiome-obesity research challenges—It is apparent that many associations of 
the descriptive findings of the microbiome with metabolic phenomena and related human 
disease have been established including gastric bypass. Most of these studies use feces, 
which may or may not be an appropriate representation of the composition of the 
microbiome throughout the intestinal tract. Additional challenges arise from the incomplete 
status of bacterial genome databases and the high number of polymorphisms. There are 
species differences among the animal models. Finally, obesity, as noted above, is a 
heterogeneous condition. Thus, establishing a cause-and-effect relationship and a basis for 
therapeutic interventions will require sorting out multiple aspects of the relationship of the 
microbiome to obesity and related comorbid disease. These investigations generate 
exceedingly large data files which require rapidly evolving skillsets among computational 
biologists for analyses.
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(VII) Gut Microbial Symbiosis and Key Enterocyte Derived Signals Influencing Health and 
Disease: Microbial Metabolomics (Blandine Laferrère)
We know that specific composition of the gut microbiome associates with pathological 
conditions such as cardio vascular disease, inflammatory bowel disease or asthma and with 
certain phenotypes like obesity and insulin resistance159. However, the mechanism by which 
the gut microbiome maintains health or contributes to diseases is unknown. Metabolomics is 
the quantitative analysis by mass-spectrometry or nuclear magnetic resonance spectroscopy 
of large numbers of low molecular weight metabolites, substrates and products in metabolic 
pathways, in bio specimens (fluids or tissue)160. Identifying metabolomic signatures and 
circulating biomarkers associated with the metabolism and functions of gut bacteria is an 
important step to understand the pathways and mechanisms by which the gut microbiome 
contributes to the development of diseases. These metabolomic biomarkers could also be 
used to track response to treatment. Discussed below are four examples of targeted 
metabolomics to the measure circulating biomarkers of microbiome metabolism: short chain 
fatty acids (SCFA), bile acids, branched chain amino acids (BCAA) and trimethylamine-N-
oxide (TMAO), and how they relate to outcomes post bariatric surgery.
SCFA – fuel and anti-carcinogen—The SCFAs are fatty acids with 2 to 6 carbons, 
bacterial metabolites produced during the colonic fermentation of indigestible 
oligosaccharides, dietary plant fibers, non-digested proteins and intestinal mucin, that are at 
the interface between the diet, the microbiota and the host161. SCFA (and medium chain FA) 
are primarily absorbed through the portal vein during lipid digestion, while long chain fatty 
acids go through chylomicrons, the lymphatic canal and the subclavian vein. SCFAs have 
many positive functions. Butyrate is the major energy source for colonocytes162–164. SCFAs 
stimulate the production of the satiety hormones GLP-1 and PYY via activation of the G-
protein-coupled receptor FFAR2165,166, a mechanism by which SCFA may modulate food 
intake167. Propionate is largely metabolized in the liver, and acetate is the main circulating 
SCFA168. SCFAs play a role in lipid metabolism and inflammation, improve insulin 
sensitivity and modulate the risk of cardio vascular disease, in part by activation of a subset 
of G protein-coupled receptors169,170. The administration of inulin-propionate ester, a 
dietary fiber, to 60 overweight humans reduced body weight, intra-abdominal adipose tissue, 
liver fat and improved insulin resistance in a 24-weeks randomized clinical trial. The 
targeted colonic delivery of inulin-propionate increased circulating PYY and GLP-1 
concentrations during a test meal and reduced subsequent food intake171. This in vivo data 
confirm the in vitro stimulation of PYY and GLP-1 from a colonic cell line by butyrate and 
propionate166. Colonic infusions of SCFA mixtures, in concentrations and ratios similar to 
the ones reached after fiber intake, increased fat oxidation, energy expenditure and PYY, and 
decreased lipolysis in overweight/obese men172. The systemic availability and metabolism 
of colonic-derived SCFAs in healthy subjects has been demonstrated using stable isotopes. 
The quantification of SCFA production from 13C-labelled fibers in the human colon can be 
done by measurement of 13C-labelled SCFA concentrations in blood173174. In that study, the 
systemic availability of colonic-administered acetate, propionate and butyrate was 36%, 9% 
and 2%, respectively. Conversion of acetate into butyrate (24%) is the most prevalent 
interconversion by the colonic microbiota. Little administered acetate was incorporated into 
cholesterol (<1%) and less than 15% in fatty acids. On average, 6% of colonic propionate 
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was incorporated into glucose. Most of SCFAs excretion occurred via the lungs after 
oxidation to 13CO2, and almost no SCFAs (less than 0.05%) were excreted into urine. There 
is no report to our knowledge of levels of circulating SCFA after bariatric surgery. However, 
fecal SCFA concentration and microbial composition was shown to be altered after 
biliopancreatic diversion and related to change in metabolism175.
Bile acids and microbiota – symbiotic relationship—Bile acids are synthesized in 
the liver from cholesterol under the control of key enzymes, stored in the gall bladder and 
excreted in the intestine upon ingestion of meals high in fat. Historically, their main function 
is to facilitate the emulsification of dietary fats and the intestinal absorption of lipids and 
lipophilic vitamins176. Bile acids undergo further transformation by the gut microbial 
enzymes, including bile salt hydrolase, through deconjugation and dehydroxylation reactions 
that generate unconjugated and secondary bile acids177. Apart from regulating secondary 
bile acid metabolism, gut microbiota also reduce the synthesis of bile acids in the liver, by a 
mechanism involving the suppression of FXR expression in the ileum178. Therefore, the gut 
microbiota contributes to the diversity and composition of the bile acid pool176,179. The 
activity of bile salt hydrolase may be modified in colon cancer and or liver disease. In the 
gut, bile acids control bacterial overgrowth and microbiome composition180–182. We also 
know that bile acids have carcinogenic potential183,184,185. In addition to their role in lipid 
digestion and as bacteriostatic agents, bile acids signal a variety of systems in the liver and 
intestine by interaction with multiple nuclear receptors186 and play a role in glucose and 
lipid metabolism187,188. Dietary factors such as prebiotics play important roles in the growth 
of intestinal microbiota and bile acids metabolism. Fecal bile acid profiling, as opposed to 
circulating bile acids, may be a better non-invasive tool to monitor the intestinal 
environment189. Many studies have shown an increase of circulating bile acids pool after 
RYGB15,190,191. However, the increased concentration of circulating bile acids and the 
change in the composition of conjugated bile acids do not seem to parallel the observed 
GLP-1 rise after the same surgery as noted in some studies191.
Protein and amino acids—Bacterial fermentation of proteins in distal colon can produce 
ammonia which can act as tumor promotor. Fermentation of aromatic amino acid tyrosine 
and tryptophan by colonic bacteria can produce phenols and indoles respectively. Phenols, 
such as p-cresol, may be pro-carcinogen in colon CA192. Essential amino acids, not 
synthesized in the body, are provided by the diet and de novo biosynthesis by gut bacteria. 
The intestinal microbiota is involved in the utilization and catabolism of several amino acids 
originating from the diet and from endogenous proteins. These amino acids can serve as 
precursors for the synthesis of bacterial products such as SCFAs. Gut bacteria may 
contribute to the branched chain amino acid (BCAA) signature associated with insulin 
resistance. Circulating BCAAs have long been associated with obesity and insulin 
resistance193,194,195,196,197 and can predict future type 2 diabetes198. Their concentration 
decreases after interventions that improve insulin sensitivity, such as surgical weight loss by 
RYGB199. Circulating BCAA concentrations are modulated by their metabolism in adipose 
tissue200 and, perhaps, also by the microbiome201. The altered gut bacterial composition in 
individuals with obesity and type 2 diabetes may contribute to their dys-metabolism by 
influencing amino acids and SCFAs bioavailability to the host. Individuals with insulin 
Jain et al. Page 12













resistance who have a serum metabolome characterized by increased levels of BCAAs, have 
a gut microbiome with an enriched biosynthetic potential for BCAAs and deprived of genes 
encoding bacterial inward transporters (from blood to gut) for these amino acid. Specific 
bacterial species driving this association were shown to induce insulin resistance, aggravate 
glucose intolerance and augment circulating levels of BCAAs in mice201.
The importance of the TMA/TMAO microbiome-host axis in health and disease
—Dietary phosphatidylcholine (lecithin), the major source of choline, is metabolized by 
intestinal lipases to form glycerophosphocholine, phosphocholine, and choline202. Choline 
containing nutrients that reach the cecum and the large bowel serve as fuel for intestinal 
bacteria, producing trimethylamine (TMA). TMA is oxidized to trimethylamine-N-oxide 
(TMAO) in the liver. TMAO enhances the accumulation of cholesterol in macrophages, the 
deposition of foam cells in arterial walls and the formation of atherosclerosis, all factors 
associated with an increased risk of cardiovascular disease and death203,204. Circulating 
choline can also be oxidized to betaine, a metabolite involved in methylation reactions and 
detoxification of homocysteine, in the liver and in the kidneys. In humans, elevated plasma 
concentrations of TMAO, choline and betaine are associated with an increased risk of a 
major adverse cardiovascular event, even after adjusting for traditional risk factors. The role 
of the gut microbiota in TMAO production was demonstrated in vivo. The acute rise of 
circulating TMAO after an oral phosphatidyl challenge can be suppressed with 
antibiotics205206. Paradoxically, circulating TMAO levels are elevated after RYGB, a surgery 
associated with large weight loss, decreased inflammation and cardiovascular risk207.
(VIII) Microbiome Host Mucosal Interactions: The Role of Epigenetics (Richard 
Kellermayer)
Epigenetics defines molecular mechanisms that influence pre-translational gene expression 
independently from the genetic code. Epigenetic processes can respond to environmental 
changes and have been implicated as important participants in the developmental origins of 
human diseases208. Secondary to environmental plasticity, the host epigenome in mammals 
carries the potential to communicate with the commensal microbiota through direct and 
indirect mechanisms209.
With respect to obesity, epigenetic regulation of body composition210 and physical 
activity211 through prenatal/early life exposures are intense areas of research. Intermediates 
of energy metabolism are co-factors in epigenetically mediated chromatin, and secondary 
gene expression modifications. Therefore, gene regulation underlying phenotypic 
determinants of adult metabolic health may be influenced by maternal and early postnatal 
diet212. Maternal (by communicating maternal nutritional influences to the emryo) and 
individual (own) commensal microbiota are inherent participants in this environment-diet 
associated developmental programming. In fact, early developmental modulation of gut 
microbial composition leads to lasting metabolic consequences in mammals213. The clinical 
relevance of these findings is supported by the association of infantile antibiotic exposure 
and subsequently increased body mass index in children214.
Jain et al. Page 13













The ongoing importance of microbiome composition in obesity and related comorbidities is 
underscored by the beneficial effects of fecal microbiota transplantation (FMT) from lean 
individuals to obese patients with metabolic syndrome215. This therapeutic intervention is 
intensely being investigated in ongoing obesity related clinical trials216. Importantly, a 
recent controlled study on FMT from lean donors into obese individuals showed a transient 
improvement in insulin sensitivity in those recipients who had lower microbiome diversity at 
baseline (responders)217.
Recent research is also examining the potentially critical role of the microbiome in regards 
to bariatric surgery outcomes. Murine model experiments indicate that the microbiome plays 
a critical role in weight gain following transient loss of obesity218. In accordance with this 
observation, recent human translational research showed consistent increase in the Roseburia 
genus in patients with successful resolution of diabetes following both RYGB and SG 
surgery219. Such microbiome changes associated with fecal metabolite alterations, may be 
relevant for modulating epigenetic mechanisms. Importantly, Roseburia are butyrate 
producers220. Butyrate can promote epigenetic remodeling in intestinal stem cells by acting 
as a histone deacetylase inhibitor221. This example signifies the potential for bariatric 
surgery induced microbiome modification to alter host physiology, which requires intense 
exploration in the future.
(IX) Gut Microbiota and Obesity: Changes Post Bariatric Surgery – Clinical Perspective 
(John K. DiBaise)
A better understanding of the mechanisms underlying the effectiveness of bariatric 
operations is important in order to optimize patient selection and clinical outcomes of these 
operations, and may result in the development of less invasive, novel treatments. The gut 
microbiota is now recognized to contribute to host energy harvest, storage and the 
development of obesity154,222. The relationship between the intestinal microbiota and 
obesity/adiposity has generated interest into the potential role of this complex microbial 
community as a contributing factor to the success or failure of bariatric operations.
RYGB anatomical and physiological changes may contribute to dysbiosis—
Following RYGB, a variety of environmental, systemic and anatomical changes occur that 
might directly or indirectly affect the microbial composition of the gut. Reduced gastric size 
will affect diet composition and acid exposure to the nutrients. Altered nutrient flow due to 
accelerated transit through the shortened small intestine may affect oxygen and nutrient 
exposure to the more distal gut. Altered bile acids and mixing of pancreaticobiliary 
secretions with nutrients will affect gut microbes. Changes in gut hormone production (e.g., 
GLP-1, PYY) due to altered nutrient exposure in the distal gut, and vagal nerve disruption 
may also affect gut microbe composition. Finally, other factors that may affect gut microbial 
populations post-RYGB64 include the occurrence of postoperative complications (some of 
which may require altered diet and exposure to antibiotics), altered diet (e.g., food 
intolerances), pre-existing disordered eating behaviors and, potentially, changes in exercise 
and mood.
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Gut microbe changes after RYGB—To date, only a handful of studies have been 
reported. A small pilot study, using pyrosequencing on fecal samples from morbidly obese 
individuals, normal weight subjects and patients who had successful weight loss after RYGB 
showed that RYGB resulted in increased abundances of Gammaproteobacteria and 
Verrucomicrobia and decreased Clostridia62. Higher numbers of the H2-producing Prevotella 
and H2-consuming Archaea in the obese subjects were found, suggesting a syntrophic 
relationship between certain microbes that improves the efficiency of fermentation and 
contributes to the development of obesity. In a study of 30 obese individuals and 13 lean 
controls, fecal samples were collected at baseline in all subjects and 3 months and 6 months 
after RYGB in the obese individuals223. Real-time quantitative PCR was performed to 
examine seven bacterial groups. After RYGB, Escherichia coli levels were significantly 
elevated at both 3 and 6 months compared to baseline and lean controls. Faecalibacterium 
prausnitzii, a bacteria suggested to have anti-inflammatory activity, also increased in 
abundance after RYGB but only in those individuals who were diabetic preoperatively. The 
same research group then performed deep sequencing on the same patients and found an 
increase in richness and diversity of the microbiota after RYGB with 37% of the increased 
bacteria belonging to Proteobacteria224. Seven dominant genera identified post-surgery, were 
independent of reduced calorie intake and were associated with markers of anti-
inflammation and insulin sensitivity. Using a non-obese rat model comparing RYGB to a 
sham control, Li et al. performed pyrosequencing and metabolite profiling of fecal 
samples63. Similar to the studies in humans, they found a 52-fold increase in Proteobacteria 
(bloom in Enterobacter hormaechei) with smaller decreases in both Firmicutes and 
Bacteroidetes. Increased oligosaccharide fermentation (and increased short-chain fatty 
acids), biogenesis of p-cresol, and amine generation were also detected post-RYGB. The 
same group demonstrated that this shift in microbial composition post-RYGB correlated 
with an increased cytotoxic environment highlighting a potential long-term cancer risk after 
RYGB225. It has been shown that RYGB alters the microbiota along the length of the gut but 
these changes were most substantial in the Roux limb and common channel suggesting that 
changes in microbes in the small bowel may regulate the beneficial effects post-surgery226. 
In another study using a mouse model of RYGB and comparing microbial and metabolite 
changes among two groups of mice following sham surgery with or without caloric 
restriction64 increases in Proteobacteria (Escherichia), Verrucomicrobia (Akkermansia) and 
Bacteroidetes (Alistipes) were found. These changes occurred by 1 week post-op, were 
consistent regardless of diet, were similar with both luminal and mucosal samples, and were 
detectable along the length of the gut. Moreover, when the authors transplanted the 
microbiota from all mouse groups into germ-free mice, RYGB feces recipients significantly 
decreased in body weight compared to the other groups64 providing for the first time 
empirical support for the claim that the changes in gut microbes post-RYGB contribute to 
reduced weight/adiposity.
Gut microbe changes after other bariatric operations—Important insight into the 
role of the gut microbes in the success or failure of RYGB may be obtained by studying 
changes in gut microbes occurring after other bariatric operations with less drastic 
alterations in gut anatomy and physiology. Vertical sleeve gastrectomy results in the 
resection of about 80% of the greater curvature portion of the stomach and causes a 
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restriction of food intake, acceleration of gastric emptying and alteration of gut hormones 
affecting satiety and appetite. VSG was noted to produce only modest microbial changes 
compared to RYGB219 but did lead an increase in the Bacteroidetes/Firmicutes ratio and a 
decrease in Eubacterium rectale, Ruminococcus obeum, Lachnospiraceae bacterium and F. 
prausnitzii (in those with impaired glucose tolerance only)227. VSG also led to an increase in 
malabsorption due to loss of energy-rich fatty acids in the stool, impaired bile acid 
circulation227 and resulted in greater capacity for metabolism of amino acids219. A human 
study compared gut microbial changes about 9 years after either RYGB or vertical banded 
gastroplasty (VBG), a predominantly restrictive operation228. They found significant 
differences in microbe composition between RYGB and obese patients but not between 
VBG and obesity or VBG and RYGB228. Furthermore, the two operations resulted in 
alterations of fecal and circulating metabolites in comparison to obese controls. Finally, they 
investigated a causal link by performing microbiota transplantation of human stool from the 
three groups into germ free mice. Mice colonized with RYGB and VBG microbiota 
accumulated 43% and 26% less body fat, respectively, than mice colonized with obese 
microbiota. Additionally, RYBG colonized mice had lower respiratory quotient than the 
other groups suggesting a decreased utilization of carbohydrates and an increased utilization 
of lipids. Finally, results from a retrospective study comparing RYGB and adjustable gastric 
banding (AGB), another mostly restrictive operation, to lean and obese control subjects 
found that RYGB and lean patients had higher microbial diversity and evenness than the 
other groups229. Bacilli, Gammaproteobacteria, and Prevotellaceae were the microbial 
signatures discriminating RYGB microbiota from lean and obese controls. 
Gammaproteobacteria and Bacilli also discriminated RYGB from AGB while Flavobacteriia 
and Porphyromonadacea discriminated AGB subjects from the non-surgical subjects. RYGB 
had higher butyrate, propionate and branch chain fatty acids230 (saturated fatty acids which 
have methyl branches on the carbon chain, usually noted in bacteria) than the other groups, 
implicating fatty acid signaling, which stimulate appetite regulating peptides, as a 
mechanism of action of RYGB. The available data, while encouraging, are limited by the 
small number of subjects, relatively short duration of follow-up, lack of standardization for 
obesity-related comorbidities and medication use, and different techniques used to probe the 
microbial communities present.
(X) Understanding the Clinical Implications of Therapeutic Bariatric Interventions (Robert 
G. Martindale)
The numerous potential interventions in the management of obesity are almost limitless 
today. Endeavors focused at weight loss and metabolic management of obesity using 
interventions ranging from behavioral modification, to pharmaceutical agents28, to 
endoscopic devices like intra-gastric balloons231, absorption barriers and various methods of 
gastric plication to the bariatric surgical procedures make decisions on the optimal choice of 
weight loss method difficult. Weight management now requires a very individualized 
approach232. Of these interventions the bariatric surgical procedures are currently the most 
durable with 20 year outcome data now available for RYGB and BPD and 10 year outcome 
data for sleeve gastrectomy233,234. Continued follow-up of these patients and well-designed 
trials have shown the co-morbidities associated with obesity are dramatically decreased 
following successful weight loss including type 2 DM, obstructive sleep apnea, 
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hypertension, several cancers and even mortality. Although successful in managing weight 
loss bariatric surgery is not without significant complications which are often ignored or 
understated by the “business” of bariatric surgery235.
The previous concept of bariatric surgery being a decision between malabsorption procedure 
and restrictive procedure is very naive and the metabolic changes associated with bariatric 
surgery are much more complex than ever anticipated. The future is bright for the study and 
management of obesity with the recent exponential increase in understanding of the 
complexity of obesity. With “Big Data”, a better understanding of the >30+ peptides 
involved in appetite control, the importance of bile salts and the microbiome in metabolic 
regulation has offered a new focus for the metabolic management of obesity236,237. The 
potential for therapeutic interventions with bile salts or their receptor antagonist30,39,238 has 
changed the focus and approach to the bariatric patient. Emerging data also points to a 
rebalancing of satiety signals post-surgery via resensitization of the gut-brain axis which 
could be a contributor to the improved outcomes239. Mechanistic pathways mediating such 
signaling remain a major research focus.
Potential answers and approaches to the global obesity crisis are within reach but this will 
take a concerted effort on not only with the health care professionals but also the general 
public. Government incentives and sponsored education to all levels of the public focused to 
draw attention to the problem of obesity will be needed. The importance of major dietary 
changes and exercise cannot be understated in any successful approach to weight 
management.
Final Remarks
The theme of the A.S.P.E.N. 2017 RW was to focus on research evaluating the role of the 
gut gut-derived signals in modulating outcomes post Bariatric Surgery. Gastric Bypass 
results in significant loss of fat mass. Additionally there is improvement in glucose/insulin 
signaling, hepatic steatosis and NAFLD, which by far outweigh the benefits of associated 
weight loss.
Manipulation of the gastro-intestinal tract as in RYGB results in marked increase in bile 
acids and its sub-fractions, which in gut epithelial cells activate Farnesoid X Receptor (FXR) 
followed by stimulation of Fibroblast Growth Factor – 19 (FGF19) signaling to liver, thus in 
turn regulating bile acid synthesis. Additionally GLP-1 rapidly increases after RYGB with 
favorable lipid and glycemic effects. Furthermore, hepatic and gut nuclear factors as well as 
bile acid pathways, (specifically FXR, TGR5 and GLP axis), modulated post bariatric 
surgery, are also known to influence gut microbiota colonization.
Recent data also highlights the importance of applied microbial metabolomics to understand 
the role of gut microbiome as a mediator between diet and metabolism. Coupling microbial 
analysis with targeted and untargeted metabolomics analysis of not only circulating 
metabolites but also stool and gut tissue analysis, coupled with sophisticated statistical 
methods applied to multi-omics analysis, will allow us to discover mechanistic links and 
pathways associating microbial metabolism with health and disease. However, the 
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complexity of microbiome metabolism, with multiple cross-talk between bacteria species, 
represent a challenge to identify novel treatment targets.
Overall, given the remarkable durability, after bariatric surgery in obesity and its related co-
morbidities, lessons learned at this workshop point to the irrefutable role of gut derived 
signals in modulating the post-operative course after bariatric surgery. Efforts exploring this 
exciting pathway may even lead to novel non-invasive/non-surgical interventions for the 
worldwide obesity epidemic.
In summary the 2017 ASPEN Research Workshop focused on the novel idea that gut derived 
signals modulates gastric bypass outcomes. The workshop brought together clinicians and 
researchers across the scientific spectrum. Such unique interaction and exchange of 
knowledge between investigators and clinicians greatly promoted an engaging discussion 
with a great potential for translation of basic findings into clinical practice. Further, the 
research workshop engaged in direct outreach to other research communities and greatly 
helped in collaborations across organizations and disciplines.
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